AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$54.53
-0.26 (-0.47%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$54.79
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
29,783

10-day average volume:
5,574,523
29,783

SLQT FINAL DEADLINE ALERT: Hagens Berman Encourages SelectQuote (SLQT) Investors with $150K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending

9:32 am ET October 14, 2021 (Newsfile) Print

San Francisco, California--(Newsfile Corp. - October 14, 2021) -  Hagens Berman urges SelectQuote, Inc. (NYSE: SLQT) investors with significant losses to submit your losses now.

Class Period: May 20, 2020 - Aug. 25, 2021

Lead Plaintiff Deadline: Oct. 15, 2021

Visit:www.hbsslaw.com/investor-fraud/SLQT

Contact An Attorney Now:SLQT@hbsslaw.com

844-916-0895

SelectQuote, Inc. (SLQT) Securities Fraud Class Action:

SelectQuote is a direct-to-consumer distribution platform that offers complex senior health, life, and auto & home insurance policies from a curated panel of insurance carriers. A significant majority of the policies SelectQuote sells are Medicare Advantage and Medicare Supplement policies, which are grouped by their effective date into yearly cohorts.

The action alleges that, throughout the Class Period, Defendants made false and misleading statements regarding the rapid policy disenrollment it had been experiencing, and as a result the Company's reported revenues, earnings, accounts receivable, and lifetime value of commissions per approved policy were improperly inflated.

The truth emerged through a series of partial disclosures beginning on May 11, 2021, when SelectQuote disclosed its Q4 2020 financial reports would be impacted by a negative cohort and tail adjustments, which management attributed to the Medicare Advantage Open Enrollment Period ("OEP") and increased "switching activity."

Then, on Aug. 25, 2021, SelectQuote revealed that lack of policy renewals affected both the 2019 and 2020 cohorts, and it would include a $65 million placeholder for the risk of additional cohort tail adjustment for the following year.

These events sent the price of SelectQuote shares crashing lower.

If you invested in SelectQuote and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding SelectQuote should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SLQT@hbsslaw.com.

# # #

About Hagens Berman

Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99567

comtex tracking

COMTEX_395187771/2523/2021-10-14T09:32:31

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.